{"transactions":[{"id":690496,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:43:58.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":22350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":22350,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":22350},"source":{"system":"sec-edgar","filing":"0001193125-26-344874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526344874/ownership.xml","form_type":"4"}},{"id":745898,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T22:32:56.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":4.3,"expiration_date":"2036-06-03","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001193125-26-262279","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526262279/ownership.xml","form_type":"4"}},{"id":748093,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-05T18:35:37.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company."}],"balance_after":12500,"derivative":{"exercise_price":30.91,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001193125-26-259236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526259236/ownership.xml","form_type":"4"}},{"id":749348,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2026-06-04T20:28:16.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":35000,"derivative":{"exercise_price":13.45,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526257488/ownership.xml","form_type":"4"}},{"id":841319,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-16T20:11:55.000Z","date":"2026-03-12","kind":"other","planned":false,"acquired":true,"shares":4199,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"NEA Partners 13, L.P. (\"NEA Partners 13\") made a pro rata distribution for no consideration of shares of Common Stock of the Issuer to its limited partners on March 12, 2026. The Edward Timothy Mathers Revocable Trust (the \"Mathers Trust\") received 4,199 shares of Common Stock of the Issuer in the distribution by NEA Partners 13 on March 12, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of the Mathers Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by the Mathers Trust in which the Reporting Person has no pecuniary interest."}],"balance_after":14168,"source":{"system":"sec-edgar","filing":"0001193125-26-108351","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526108351/ownership.xml","form_type":"4"}},{"id":845743,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-13T00:15:07.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104715","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526104715/ownership.xml","form_type":"4"}},{"id":845742,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-13T00:15:07.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104715","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526104715/ownership.xml","form_type":"4"}},{"id":860998,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-04T21:40:00.000Z","date":"2026-03-02","kind":"other","planned":false,"acquired":true,"shares":4198,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"NEA Partners 13, L.P. (\"NEA Partners 13\") made a pro rata distribution for no consideration of shares of Common Stock of the Issuer to its limited partners on March 2, 2026. The Edward Timothy Mathers Revocable Trust (the \"Mathers Trust\") received 4,198 shares of Common Stock of the Issuer in the distribution by NEA Partners 13 on March 2, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of the Mathers Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by the Mathers Trust in which the Reporting Person has no pecuniary interest."}],"balance_after":9969,"source":{"system":"sec-edgar","filing":"0001193125-26-091684","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526091684/ownership.xml","form_type":"4"}},{"id":909636,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737962},"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909635,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909634,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909633,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1619240},"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909632,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":937500,"price":16,"value":15000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6035038,"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909631,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5097538,"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909630,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":4359576,"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909629,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":2989408,"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909628,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1619240,"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":954985,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-01-02T21:16:56.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":3911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":15310,"source":{"system":"sec-edgar","filing":"0001193125-26-000942","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526000942/ownership.xml","form_type":"4"}},{"id":1023046,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1352200},"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023045,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":125000,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":550323},"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023044,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":false,"shares":124085,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":124085},"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023043,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":124085,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":124085,"derivative":{"exercise_price":0.01,"exercise_date":"2025-10-02","expiration_date":"2030-10-02","underlying":"Common Stock","underlying_shares":124085},"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023042,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":607536,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrants became exercisable as to 371,187 shares on April 30, 2024, 28,399 shares on June 21, 2024, 185,595 shares on October 2, 2024 and 22,355 shares on September 26, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The warrants became exercisable as to 371,187 shares on April 30, 2024, 28,399 shares on June 21, 2024, 185,595 shares on October 2, 2024 and 22,355 shares on September 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":607536},"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023041,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":1656789,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The warrants became exercisable as to 828,395 shares on August 29, 2023, 552,263 shares on September 18, 2023, 100,606 shares on November 1, 2023 and 175,525 shares on December 20, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The warrants became exercisable as to 828,395 shares on August 29, 2023, 552,263 shares on September 18, 2023, 100,606 shares on November 1, 2023 and 175,525 shares on December 20, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":1656789},"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023040,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37700,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":509780},"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023039,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":330194},"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023038,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":false,"shares":186128,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":186128},"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023037,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":186128,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":186128,"derivative":{"exercise_price":0.01,"exercise_date":"2025-10-02","expiration_date":"2030-10-02","underlying":"Common Stock","underlying_shares":186128},"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023036,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":189195,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":189195},"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023035,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2384873,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023034,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":182,"price":6.75,"value":1228.5,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2384873,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023033,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":true,"shares":124085,"price":0.01,"value":1240.85,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2385055,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023032,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":900,"price":6.75,"value":6075.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2260970,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023031,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":607536,"price":0.01,"value":6075.36,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2261870,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023030,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":2455,"price":6.75,"value":16571.25,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1654334,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023029,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":1656789,"price":0.01,"value":16567.89,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1656789,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023028,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":674554,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023027,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":276,"price":6.75,"value":1863.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":674554,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023026,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":true,"shares":186128,"price":0.01,"value":1861.28,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":674830,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023025,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":280,"price":6.75,"value":1890.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":488702,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1023024,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:50:58.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":189195,"price":0.01,"value":1891.95,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":488982,"source":{"system":"sec-edgar","filing":"0001193125-25-232136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232136/ownership.xml","form_type":"4"}},{"id":1026631,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-10-02T20:29:28.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":11399,"source":{"system":"sec-edgar","filing":"0001193125-25-228402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312525228402/ownership.xml","form_type":"4"}},{"id":1094556,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-07-02T20:33:22.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":4694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":7274,"source":{"system":"sec-edgar","filing":"0000950170-25-093063","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025093063/ownership.xml","form_type":"4"}},{"id":1100379,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T23:02:08.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":21950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":21950,"derivative":{"exercise_price":2.05,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":21950},"source":{"system":"sec-edgar","filing":"0000950170-25-091134","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854270/000095017025091134/ownership.xml","form_type":"4"}},{"id":1100906,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-26T20:45:07.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":4712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."}],"balance_after":4712,"derivative":{"underlying":"Common Stock","underlying_shares":4712},"source":{"system":"sec-edgar","filing":"0000950170-25-090454","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025090454/ownership.xml","form_type":"4"}},{"id":1100905,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T20:45:07.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":7037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":7037,"derivative":{"exercise_price":63.66,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":7037},"source":{"system":"sec-edgar","filing":"0000950170-25-090454","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025090454/ownership.xml","form_type":"4"}},{"id":1103539,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-23T20:57:17.000Z","date":"2025-06-18","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000950170-25-089052","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025089052/ownership.xml","form_type":"4"}},{"id":1103538,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-23T20:57:17.000Z","date":"2025-06-18","kind":"exercise","planned":false,"acquired":true,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0000950170-25-089052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025089052/ownership.xml","form_type":"4"}},{"id":1111212,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2025-06-13T20:09:28.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":6.25,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-25-086165","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025086165/ownership.xml","form_type":"4"}},{"id":1119783,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-06-06T15:29:01.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company."}],"balance_after":16000,"derivative":{"exercise_price":11.86,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-082773","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025082773/ownership.xml","form_type":"4"}},{"id":1128996,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T21:05:33.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":7650,"derivative":{"exercise_price":2.44,"expiration_date":"2035-05-27","underlying":"Class A Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0000950170-25-079841","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025079841/ownership.xml","form_type":"4"}},{"id":1182841,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-04-02T20:48:28.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":2580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The RSUs were granted to the Reporting Person in lieu of a quarterly cash retainer, at the election of the Reporting Person, under the Issuer's Outside Director Compensation Policy."}],"balance_after":2580,"source":{"system":"sec-edgar","filing":"0000950170-25-049473","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025049473/ownership.xml","form_type":"4"}},{"id":1212503,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-11T20:28:11.000Z","date":"2025-03-07","kind":"grant","planned":false,"acquired":true,"shares":43900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying this option vest on the first anniversary of the date of grant, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":43900,"derivative":{"exercise_price":3.52,"expiration_date":"2035-03-06","underlying":"Common Stock","underlying_shares":43900},"source":{"system":"sec-edgar","filing":"0000950170-25-037187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854270/000095017025037187/ownership.xml","form_type":"4"}},{"id":1389179,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-08T23:27:58.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":15300,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0000950170-24-113604","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017024113604/ownership.xml","form_type":"4"}},{"id":1392041,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-03T22:37:11.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":185595,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":556782,"derivative":{"exercise_price":0.01,"exercise_date":"2024-10-02","expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":185595},"source":{"system":"sec-edgar","filing":"0000950170-24-112614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024112614/ownership.xml","form_type":"4"}},{"id":1392040,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-03T22:37:11.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":61865,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":185594,"derivative":{"exercise_price":0.01,"exercise_date":"2024-10-02","expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":61865},"source":{"system":"sec-edgar","filing":"0000950170-24-112614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024112614/ownership.xml","form_type":"4"}},{"id":1405219,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-09-18T00:28:00.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":25142840,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2091383},"source":{"system":"sec-edgar","filing":"0000950170-24-107558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107558/ownership.xml","form_type":"4"}},{"id":1405218,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-09-18T00:28:00.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":12299854,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1023103},"source":{"system":"sec-edgar","filing":"0000950170-24-107558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107558/ownership.xml","form_type":"4"}},{"id":1405217,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:28:00.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":16,"value":8000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":3614486,"source":{"system":"sec-edgar","filing":"0000950170-24-107558","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107558/ownership.xml","form_type":"4"}},{"id":1405216,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:28:00.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":2091383,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":3114486,"source":{"system":"sec-edgar","filing":"0000950170-24-107558","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107558/ownership.xml","form_type":"4"}},{"id":1405215,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:28:00.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":1023103,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1023103,"source":{"system":"sec-edgar","filing":"0000950170-24-107558","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107558/ownership.xml","form_type":"4"}},{"id":1407719,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T21:11:19.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":15963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":15963,"derivative":{"exercise_price":16,"expiration_date":"2034-09-11","underlying":"Common Stock","underlying_shares":15963},"source":{"system":"sec-edgar","filing":"0000950170-24-106456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024106456/ownership.xml","form_type":"4"}},{"id":1455377,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-12T20:30:25.000Z","date":"2024-07-10","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2025 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":62500,"derivative":{"exercise_price":0.31,"expiration_date":"2034-07-09","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0000950170-24-083230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854270/000095017024083230/ownership.xml","form_type":"4"}},{"id":1469372,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-25T20:38:22.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000950170-24-077346","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017024077346/ownership.xml","form_type":"4"}},{"id":1469371,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T20:38:22.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":true,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000950170-24-077346","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017024077346/ownership.xml","form_type":"4"}},{"id":1472908,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-21T01:43:09.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."}],"balance_after":4000,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000950170-24-075835","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017024075835/ownership.xml","form_type":"4"}},{"id":1472907,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T01:43:09.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":14000,"derivative":{"exercise_price":41.39,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0000950170-24-075835","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017024075835/ownership.xml","form_type":"4"}},{"id":1473209,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-20T16:30:03.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 18, 2024. The shares underlying the option are scheduled to vest as to 100% of the shares on June 18, 2025, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date."}],"balance_after":28000,"derivative":{"exercise_price":4.4,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0000950170-24-075631","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024075631/ownership.xml","form_type":"4"}},{"id":1478683,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2024-06-14T20:40:23.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 13, 2024. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of\ngrant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":30000,"derivative":{"exercise_price":2.77,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-073751","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017024073751/ownership.xml","form_type":"4"}},{"id":1536041,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-24T21:00:19.000Z","date":"2024-04-22","kind":"purchase","planned":false,"acquired":true,"shares":17857,"price":56,"value":999992.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on April 22, 2024 pursuant to a Subscription Agreement dated April 17, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1090793,"source":{"system":"sec-edgar","filing":"0000950170-24-047681","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017024047681/ownership.xml","form_type":"4"}},{"id":1543786,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-04-10T23:21:44.000Z","date":"2024-04-08","kind":"purchase","planned":false,"acquired":true,"shares":371187,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":371187,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":371187},"source":{"system":"sec-edgar","filing":"0000950170-24-043488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024043488/ownership.xml","form_type":"4"}},{"id":1543785,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-04-10T23:21:44.000Z","date":"2024-04-08","kind":"purchase","planned":false,"acquired":true,"shares":123729,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":123729,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":123729},"source":{"system":"sec-edgar","filing":"0000950170-24-043488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024043488/ownership.xml","form_type":"4"}},{"id":1702189,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-12-21T22:01:40.000Z","date":"2023-12-19","kind":"purchase","planned":false,"acquired":true,"shares":175525,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1656789,"derivative":{"exercise_price":0.01,"exercise_date":"2023-12-20","expiration_date":"2028-08-29","underlying":"Common Stock","underlying_shares":175525},"source":{"system":"sec-edgar","filing":"0001209191-23-059454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919123059454/doc4.xml","form_type":"4"}},{"id":1751386,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-11-02T22:48:55.000Z","date":"2023-10-31","kind":"purchase","planned":false,"acquired":true,"shares":100606,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1481264,"derivative":{"exercise_price":0.01,"exercise_date":"2023-11-01","expiration_date":"2028-08-29","underlying":"Common Stock","underlying_shares":100606},"source":{"system":"sec-edgar","filing":"0001209191-23-054217","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919123054217/doc4.xml","form_type":"4"}},{"id":1777350,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-09-19T22:26:13.000Z","date":"2023-09-15","kind":"purchase","planned":false,"acquired":true,"shares":552263,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1380658,"derivative":{"exercise_price":0.01,"exercise_date":"2023-09-18","expiration_date":"2028-08-29","underlying":"Common Stock","underlying_shares":552263},"source":{"system":"sec-edgar","filing":"0001209191-23-050065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919123050065/doc4.xml","form_type":"4"}},{"id":1807361,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-08-16T01:58:57.000Z","date":"2023-08-11","kind":"purchase","planned":false,"acquired":true,"shares":828395,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity L.P. (\"NEA 18 VGE\"), the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity L.P. (\"NEA 18 VGE\"), the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":828395,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":828395},"source":{"system":"sec-edgar","filing":"0001209191-23-045937","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919123045937/doc4.xml","form_type":"4"}},{"id":1827048,"issuer":{"id":4900,"kind":"organization","name":"Savara Inc","symbol":"SVRA"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-19T23:10:33.000Z","date":"2023-07-17","kind":"purchase","planned":false,"acquired":true,"shares":333333,"price":3,"value":999999.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reports the purchase of shares in the underwritten public offering of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"). NEA 17 is the sole member of Growth Equity Opportunities 17, LLC (\"GEO 17\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by GEO 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":24471264,"source":{"system":"sec-edgar","filing":"0001209191-23-042802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1160308/000120919123042802/doc4.xml","form_type":"4"}},{"id":1840899,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2023-06-30T20:14:28.000Z","date":"2023-06-28","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 28, 2023. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and\n(ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service\nas a director, employee or consultant of the Issuer."}],"balance_after":30000,"derivative":{"exercise_price":2.27,"expiration_date":"2033-06-27","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-040303","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919123040303/doc4.xml","form_type":"4"}},{"id":1844074,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T19:46:34.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation."}],"balance_after":30000,"derivative":{"exercise_price":0.504,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-039666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919123039666/doc4.xml","form_type":"4"}},{"id":1844975,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-23T20:58:18.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-23-039436","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919123039436/doc4.xml","form_type":"4"}},{"id":1844974,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T20:58:18.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":14000,"derivative":{"exercise_price":18.47,"expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-23-039436","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919123039436/doc4.xml","form_type":"4"}},{"id":1848002,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-21T23:24:52.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2024 Annual Meeting, subject to the reporting person's continued service through the\napplicable vesting date."}],"balance_after":62500,"derivative":{"exercise_price":0.99,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001209191-23-038925","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854270/000120919123038925/doc4.xml","form_type":"4"}},{"id":1854365,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T16:16:14.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 13, 2023. The shares underlying the option are scheduled to vest as to 100% of the shares on June 13, 2024, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date."}],"balance_after":16000,"derivative":{"exercise_price":6.18,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-23-037320","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919123037320/doc4.xml","form_type":"4"}},{"id":1861926,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T00:09:20.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":17500,"derivative":{"exercise_price":9.01,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-23-035585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919123035585/doc4.xml","form_type":"4"}},{"id":1968582,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-06T18:47:57.000Z","date":"2023-03-02","kind":"other","acquired":true,"shares":5771,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Edward Timothy Mathers Revocable Trust (the \"Mathers Trust\") received 5,771 shares of Common Stock of the Issuer in the distribution by NEA Partners 13, L.P.  on March 2, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of the Mathers Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the 1934 Act, as amended, or otherwise of such portion of the securities held by the Mathers Trust in which\nthe Reporting Person has no pecuniary interest."}],"balance_after":5771,"source":{"system":"sec-edgar","filing":"0001209191-23-016175","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919123016175/doc4.xml","form_type":"4"}},{"id":2098391,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-12-02T17:09:24.000Z","date":"2022-12-01","kind":"disposition_to_issuer","acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and [Continued on Note 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[Continuation of Note 1] (y) one non-tradable contingent value right (\"CVR\") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and [Continued on Note 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[Continuation of Note 1] (y) one non-tradable contingent value right (\"CVR\") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."}],"balance_after":0,"derivative":{"exercise_price":4.21,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-22-059455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000120919122059455/doc4.xml","form_type":"4"}},{"id":2134750,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2022-10-19T23:59:51.000Z","date":"2022-10-17","kind":"purchase","acquired":true,"shares":100000,"price":1000,"value":100000000.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock has no expiration date. At any time after the third anniversary of the original issuance date, if the closing price per share of Common Stock is greater than 287% of the then applicable conversion price (initially $4.07) for (x) at least 20 trading days in any period of 30 consecutive trading days and (y) the last trading day immediately before the Issuer provides notice of its election to convert, the Issuer may elect to convert all of the Series B Preferred Stock into the relevant number of shares of Common Stock. [Continued on Note 3]"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[Continuation of Note 2] At any time following the fifth anniversary of the original issuance date, the Issuer may redeem all of the Series B Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the original issuance date and (B) 100% if the redemption occurs at any time on or after the seventh anniversary of the original issuance date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":70574720},"source":{"system":"sec-edgar","filing":"0001209191-22-054144","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919122054144/doc4.xml","form_type":"4"}},{"id":2134749,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2022-10-19T23:59:51.000Z","date":"2022-10-17","kind":"purchase","acquired":true,"shares":37700,"price":1000,"value":37700000.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock has no expiration date. At any time after the third anniversary of the original issuance date, if the closing price per share of Common Stock is greater than 287% of the then applicable conversion price (initially $4.07) for (x) at least 20 trading days in any period of 30 consecutive trading days and (y) the last trading day immediately before the Issuer provides notice of its election to convert, the Issuer may elect to convert all of the Series B Preferred Stock into the relevant number of shares of Common Stock. [Continued on Note 3]"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[Continuation of Note 2] At any time following the fifth anniversary of the original issuance date, the Issuer may redeem all of the Series B Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the original issuance date and (B) 100% if the redemption occurs at any time on or after the seventh anniversary of the original issuance date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":37700,"derivative":{"underlying":"Common Stock","underlying_shares":26606669},"source":{"system":"sec-edgar","filing":"0001209191-22-054144","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000120919122054144/doc4.xml","form_type":"4"}},{"id":2207127,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-15T22:09:58.000Z","date":"2022-07-13","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in 36 substantially equal monthly installments over three years from July 13, 2022, subject to the reporting person's continued service through the applicable vesting date. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2022 Equity Incentive Plan with the U.S. Securities and Exchange Commission."}],"balance_after":125000,"derivative":{"exercise_price":1.75,"expiration_date":"2032-07-12","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-22-042301","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854270/000120919122042301/doc4.xml","form_type":"4"}},{"id":2221183,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-27T17:08:09.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 23, 2022. The shares underlying the option will fully vest on the earlier of (i) June 23, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders."}],"balance_after":16000,"derivative":{"exercise_price":4.21,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-22-039500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000120919122039500/doc4.xml","form_type":"4"}},{"id":2222825,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2022-06-23T21:04:07.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 23, 2022. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":20000,"derivative":{"exercise_price":2.27,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-038976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919122038976/doc4.xml","form_type":"4"}},{"id":2232708,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-14T16:32:59.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":9367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 10, 2022. The shares underlying the option are scheduled to vest as to 100% of the shares on June 10, 2023, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date."}],"balance_after":9367,"derivative":{"exercise_price":4.38,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":9367},"source":{"system":"sec-edgar","filing":"0001209191-22-036697","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919122036697/doc4.xml","form_type":"4"}},{"id":2233807,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T20:45:50.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee-director's continued service as a director of the Corporation."}],"balance_after":27000,"derivative":{"exercise_price":1.17,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-22-036358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919122036358/doc4.xml","form_type":"4"}},{"id":2235607,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T20:35:15.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 8, 2023 or (ii) the date of the Issuer's next annual meeting of the stockholders."}],"balance_after":20000,"derivative":{"exercise_price":4.15,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-035920","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919122035920/doc4.xml","form_type":"4"}},{"id":2242496,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-06T22:23:17.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2023 annual stockholder meeting."}],"balance_after":17000,"derivative":{"exercise_price":23.51,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-22-034671","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919122034671/doc4.xml","form_type":"4"}},{"id":2243995,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-03T21:26:30.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the earlier of June 1, 2023 or the day prior to the date of the Issuer's 2023 annual meeting of the stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":17500,"derivative":{"exercise_price":2.09,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-22-034225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919122034225/doc4.xml","form_type":"4"}},{"id":2297603,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2022-04-13T21:32:47.000Z","date":"2022-04-11","kind":"grant","acquired":true,"shares":3000000,"price":1.899,"value":5697000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on April 11, 2022 pursuant to a Securities Purchase Agreement dated April 6, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable immediately and will be exercisable until exercised in full. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 9.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise, which percentage may be increased or decreased at the holder's election upon 61 days' notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable immediately and will be exercisable until exercised in full. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 9.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise, which percentage may be increased or decreased at the holder's election upon 61 days' notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 18 VG GP, LLC, which is the sole general partner of NEA Partners 18 VG, L.P. (\"NEA Partners 18 VG\"). NEA Partners 18 VG is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":3000000,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":3000000},"source":{"system":"sec-edgar","filing":"0001209191-22-024323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919122024323/doc4.xml","form_type":"4"}},{"id":2297602,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-13T21:32:47.000Z","date":"2022-04-11","kind":"grant","acquired":true,"shares":948948,"price":1.9,"value":1803001.2,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on April 11, 2022 pursuant to a Securities Purchase Agreement dated April 6, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 18 VG GP, LLC, which is the sole general partner of NEA Partners 18 VG, L.P. (\"NEA Partners 18 VG\"). NEA Partners 18 VG is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":948948,"source":{"system":"sec-edgar","filing":"0001209191-22-024323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919122024323/doc4.xml","form_type":"4"}},{"id":2649559,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C convertible preferred Stock","published_at":"2021-06-30T22:06:59.000Z","date":"2021-06-28","kind":"exercise","acquired":false,"shares":2361912,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":669002},"source":{"system":"sec-edgar","filing":"0001209191-21-044044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919121044044/doc4.xml","form_type":"4"}},{"id":2649558,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2021-06-30T22:06:59.000Z","date":"2021-06-28","kind":"exercise","acquired":false,"shares":11500000,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3257328},"source":{"system":"sec-edgar","filing":"0001209191-21-044044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000120919121044044/doc4.xml","form_type":"4"}}],"next_cursor":"2021-06-30T22:06:59.000000Z,2649558"}